It will receive technology transfer from Gilead for manufacturing this drug. Dr Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing this drug in the respective countries.
Gilead Sciences has already signed 22 non-exclusive voluntary agreements with six generic pharmaceutical companies in India and Pakistan to manufacture and distribute remdesivir.Dr Reddy’s Laboratories has entered into a non-exclusive licensing agreement with US-based Gilead Sciences to register, manufacture and sell Gilead’s investigational drug Remdesivir, a potential treatment for Covid-19, in 127 countries, including India.
It will receive technology transfer from Gilead for manufacturing this drug. Dr Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing this drug in the respective countries.
Gilead Sciences has already signed 22 non-exclusive voluntary agreements with six generic pharmaceutical companies in India and Pakistan to manufacture and distribute remdesivir.
The manufacturers include Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Life Sciences, Zydus Cadila and Mylan.
Remdesivir, an investigational therapy developed by Gilead, received emergency use authorization by the USFDA to treat hospitalised patients with severe Covid-19 illness.
India currently does not manufacture Remdesivir.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
